Bradford patient gets revolutionary new treatment for lung disease (From Bradford Telegraph and Argus)
Get involved: send your pictures, video, news and views by texting TANEWS to 80360, or email
Pudsey patient gets revolutionary new treatment for lung disease
A Bradford patient will be the first in the world to trial a “revolutionary “new treatment which could make breathing easier for millions of people suffering from a debilitating lung condition.
COPD (chronic obstructive pulmonary disease) sufferer David Moone will start using a special inhaler which medics hope is not only a better treatment than currently available, but also a safer one with fewer side effects.
The director of research at Bradford Institute for Health Research (BIHR) said having the first person in the world trial the treatment was “like winning an Olympic gold medal”.
And Bradford Teaching Hospitals’ consultant respiratory physician Dr Dinesh Saralaya said it meant Bradford patients were getting the best treatment available. “It will be revolutionary. It will be a major game changer in COPD treatment. It’s going to give patients a far better symptom relief, but also be much safer,” Dr Saralaya said.
“I’m elated. I’m happy for us, but also for the city of Bradford. It gives a chance for patients in Bradford to experience the most cutting edge treatment in the world. This is huge news for Bradford.”
Bradford has the highest number of people with COPD in Yorkshire and the Humber, second only to Hull. Each year about 1,200 people are admitted to Bradford Royal Infirmary with COPD, which is primarily caused by smoking.
Dr Saralaya said it was more common in the north and pockets of deprivation in areas of Bradford contributed to high levels in the city.
It is the third time in three years that a Bradford patient is the first in the world to be recruited to a new drug research trial for COPD treatment.
Mr Moone will try a new bronchodilator – a specially designed inhaler which opens up the airways using two medicines, instead of the steroids contained in more conventional inhalers, so that air can flow into the lungs more freely and improve breathing.
Dr Saralaya said exacerbations to COPD, such as infection, were treated with a steroid inhaler, but could lead to other problems. He said: “Traditional oral bronchodilators use steroids to help relieve symptoms such as coughing, wheezing and shortness of breath in patients especially when their condition worsens. But these steroids also carry the risk of side effects such as thinning of the skin, diabetes, cataracts, reduced bone density and high blood pressure, all of which can lead to a patient being hospitalised.
“The bronchodilator we are trialing is a combination of two long-acting inhalers, which relax the lining of the breathing tubes and which I believe has the potential to revolutionise the future treatment of COPD here in the UK as it allows patients to breathe better, thereby reducing the frequency of them experiencing more severe symptoms,” he said. It will help reduce the hospitalisation of patients with COPD as it will lessen their risk of developing side effects common in conventional steroid inhalers.”
In another Bradford first, Dr Saralaya has also been named as the lead UK investigator for the one-year, global study. Altogether 200 people will be recruited and Dr Saralaya will be one of the authors on the research report when it releases its findings in 2015.